LGALS3 and Myocardial fibrosis: This aligns with previous findings, such as those by Li et al., who demonstrated galectin-3’s association with the presence, complexity, and severity of CAD, as well as its potential to predict adverse events because of its involvement in myocardial fibrosis and inflammation.